Janssen Marks First Approval Worldwide for TECVAYLI?(teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma

Teclistamab, an off-the-shelf (ready to use) subcutaneously administered therapy, induced deep and rapid responses in triple-class exposed patients with relapsed and refractory multiple myeloma1 The

Related Keywords

United States ,American ,Jenni Mildon ,Williamn Hait ,Maria Victoria Mateos ,Peter Lebowitz ,Edmond Chan ,None Of The Janssen Pharmaceutical Companies ,American Society Of Clinical Oncology ,European Commission ,Global Public Health ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Exchange Commission ,University Hospital Of Salamanca ,Companies Of Johnson ,European Medicines Agency ,European Medicines Agency Ema Priority ,Committee For Medicinal Products Human Use ,Johnson ,American Cancer Society ,Consultant Physician ,University Hospital ,Senior Director ,Area Lead Haematology ,Confidence Interval ,New England Journal ,Global Therapeutic Area Head ,Executive Vice President ,Chief External Innovation ,Medical Safety ,Global Public Health Officer ,Medicinal Products ,Human Use ,Pharmaceutical Companies ,Metabolism Retina ,Infectious Diseases Vaccines ,Janssen Cilag Limited ,Private Securities Litigation Reform Act ,Janssen Pharmaceutica ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Med Sci ,European Medicines ,Escalation Study ,Participants With Relapsed ,Refractory Multiple Myeloma ,Refractory Multiple ,Subcutaneous Daratumumab Regimens ,Participants With Multiple ,Combination With Daratumumab Subcutaneously ,Versus Daratumumab ,Today Population Factsheets ,Janssen ,Parks ,First ,Approval ,Orldwide ,Tecvayli ,Teclistamab ,Authorisation ,Glass ,Bispecific ,Ntibody ,Treatment ,Patients ,Multiple ,Myeloma ,